{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:02:09Z","timestamp":1790708529658,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Agency","award":["Next Generation EU initiative, within the framework of the National Recovery Plan, Component D, Investment D3.1.1 (project no. 2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-0173\/24-00)"],"award-info":[{"award-number":["Next Generation EU initiative, within the framework of the National Recovery Plan, Component D, Investment D3.1.1 (project no. 2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-0173\/24-00)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"DOI":"10.1007\/s43440-026-00907-w","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:09:00Z","timestamp":1790705340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tryptamide (nicotredole) revisited: re-examining a forgotten anti-inflammatory agent by large-scale target profiling and ADMET studies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-9400","authenticated-orcid":false,"given":"Katarzyna","family":"Szczepa\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4035-659X","authenticated-orcid":false,"given":"Tadeusz","family":"Karcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-674X","authenticated-orcid":false,"given":"Ryszard","family":"Bugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-947X","authenticated-orcid":false,"given":"Katarzyna","family":"Kaczorowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-3406","authenticated-orcid":false,"given":"Beata","family":"Duszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6333","authenticated-orcid":false,"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"907_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","volume":"14","author":"MJ Waring","year":"2015","unstructured":"Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14:475\u201386. https:\/\/doi.org\/10.1038\/nrd4609.","journal-title":"Nat Rev Drug Discov"},{"key":"907_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","volume":"3","author":"TP Green","year":"2009","unstructured":"Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009;3:248\u201361. https:\/\/doi.org\/10.1016\/j.molonc.2009.01.002.","journal-title":"Mol Oncol"},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","volume":"7","author":"HB Nygaard","year":"2015","unstructured":"Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7:35. https:\/\/doi.org\/10.1186\/s13195-015-0119-0.","journal-title":"Alzheimers Res Ther"},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","volume":"14","author":"MJ Cunningham","year":"2023","unstructured":"Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, et al. Pharmacological Mechanism of the Non-hallucinogenic 5-HT 2A Agonist Ariadne and Analogs. ACS Chem Neurosci. 2023;14:119\u201335. https:\/\/doi.org\/10.1021\/acschemneuro.2c00597.","journal-title":"ACS Chem Neurosci"},{"key":"907_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/1389200222666210705122913","volume":"22","author":"NE-H Daoud","year":"2021","unstructured":"Daoud NE-H, Borah P, Deb PK, Venugopala KN, Hourani W, Alzweiri M, et al. ADMET Profiling in Drug Discovery and Development: Perspectives of In Silico, In Vitro and Integrated Approaches. Curr Drug Metab. 2021;22:503\u201322. https:\/\/doi.org\/10.2174\/1389200222666210705122913.","journal-title":"Curr Drug Metab"},{"key":"907_CR7","first-page":"103","volume":"28","author":"M Sadowska-Wr\u00f3blewska","year":"1990","unstructured":"Sadowska-Wr\u00f3blewska M, Filipowicz-Sosnowska A, Eyman E, Bernacka K, Gburek Z, Kapo\u0142ka D, Stasiewicz A. Wyniki bada\u0144 klinicznych II fazy preparatu Tryptamid Polfa u chorych na przewlek\u0142e choroby reumatyczne. Reumatologia. 1990;28:103\u201311.","journal-title":"Reumatologia"},{"key":"907_CR8","first-page":"729","volume":"39","author":"ZS Herman","year":"1987","unstructured":"Herman ZS, Brus R, Soko\u0142a A, Szkilnik R, Kmieciak-Ko\u0142ada K, Zieli\u0144ski M, et al. Basic pharmacological properties of a novel antiinflammatory drug tryptamide. Pol J Pharmacol Pharm. 1987;39:729\u201336.","journal-title":"Pol J Pharmacol Pharm"},{"key":"907_CR9","first-page":"769","volume":"39","author":"D Kulig","year":"1987","unstructured":"Kulig D, Zaczy\u0144ska-Kostrakiewicz M. A comparison of anti-inflammatory, analgesic and ulcerogenic action of tryptamide, ibuprofen and piroxicam. Pol J Pharmacol Pharm. 1987;39:769\u201372.","journal-title":"Pol J Pharmacol Pharm"},{"key":"907_CR10","first-page":"19","volume":"47","author":"H Szumi\u0142o","year":"1990","unstructured":"Szumi\u0142o H. Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. Acta Pol Pharm. 1990;47:19\u201322.","journal-title":"Acta Pol Pharm"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1021\/acschemneuro.4c00480","volume":"15","author":"T Karcz","year":"2024","unstructured":"Karcz T, Szczepa\u0144ska K, Mogilski S, Moroz A, Olejarz-Maciej A, Humphrys LJ, et al. Guanidine Derivative ADS1017, a Potent Histamine H3 Receptor Antagonist with Promising Analgesic Activity and Satisfactory Safety Profile. ACS Chem Neurosci. 2024;15:4441\u201357. https:\/\/doi.org\/10.1021\/acschemneuro.4c00480.","journal-title":"ACS Chem Neurosci"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11095-007-9517-8","volume":"25","author":"X Chen","year":"2008","unstructured":"Chen X, Murawski A, Patel K, Crespi CL, Balimane PV. A Novel Design of Artificial Membrane for Improving the PAMPA Model. Pharm Res. 2008;25:1511\u201320. https:\/\/doi.org\/10.1007\/s11095-007-9517-8.","journal-title":"Pharm Res"},{"key":"907_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.1.2.175","volume":"1","author":"RB van Breemen","year":"2005","unstructured":"van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1:175\u201385. https:\/\/doi.org\/10.1517\/17425255.1.2.175.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"907_CR14","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/pharmaceutics13101563","volume":"13","author":"CL Pires","year":"2021","unstructured":"Pires CL, Pra\u00e7a C, Martins PAT, Batista de Carvalho ALM, Ferreira L, Marques MPM, et al. Re-Use of Caco-2 Monolayers in Permeability Assays\u2014Validation. Regarding Cell Monolayer Integr Pharm. 2021;13:1563. https:\/\/doi.org\/10.3390\/pharmaceutics13101563.","journal-title":"Regarding Cell Monolayer Integr Pharm"},{"key":"907_CR15","doi-asserted-by":"publisher","first-page":"127522","DOI":"10.1016\/j.bmcl.2020.127522","volume":"30","author":"K Szczepa\u0144ska","year":"2020","unstructured":"Szczepa\u0144ska K, Kincses A, Vincze K, Szyma\u0144ska E, Latacz G, Kuder KJ, et al. N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H3 receptor and cancer resistance proteins. Bioorg Med Chem Lett. 2020;30:127522. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127522.","journal-title":"Bioorg Med Chem Lett"},{"key":"907_CR16","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/molecules30234633","volume":"30","author":"AA Kaczor","year":"2025","unstructured":"Kaczor AA, Zi\u0119ba A, Karcz T, Jastrz\u0119bski MK, Szczepa\u0144ska K, Laitinen T, et al. SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation. Molecules. 2025;30:4633. https:\/\/doi.org\/10.3390\/molecules30234633.","journal-title":"Molecules"},{"key":"907_CR17","doi-asserted-by":"publisher","first-page":"20270","DOI":"10.1073\/pnas.0909411106","volume":"106","author":"JZ Long","year":"2009","unstructured":"Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci. 2009;106:20270\u20135. https:\/\/doi.org\/10.1073\/pnas.0909411106.","journal-title":"Proc Natl Acad Sci"},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112\u20139. https:\/\/doi.org\/10.1038\/nchembio711.","journal-title":"Nat Chem Biol"},{"key":"907_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/pro.5560020312","volume":"2","author":"H Levine","year":"1993","unstructured":"Levine H. Thioflavine T interaction with synthetic Alzheimer\u2019s disease \u03b2-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993;2:404\u201310. https:\/\/doi.org\/10.1002\/pro.5560020312.","journal-title":"Protein Sci"},{"key":"907_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-020209-171035","volume":"61","author":"C Patrono","year":"2010","unstructured":"Patrono C, Rocca B. The Future of Antiplatelet Therapy in Cardiovascular Disease. Annu Rev Med. 2010;61:49\u201361. https:\/\/doi.org\/10.1146\/annurev-med-020209-171035.","journal-title":"Annu Rev Med"},{"key":"907_CR21","doi-asserted-by":"publisher","first-page":"15059","DOI":"10.1016\/S0021-9258(18)95702-9","volume":"260","author":"M Haurand","year":"1985","unstructured":"Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem. 1985;260:15059\u201367.","journal-title":"J Biol Chem"},{"key":"907_CR22","doi-asserted-by":"publisher","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","volume":"50","author":"EM Smyth","year":"2009","unstructured":"Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50:S423\u20138. https:\/\/doi.org\/10.1194\/jlr.R800094-JLR200.","journal-title":"J Lipid Res"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"112217","DOI":"10.1016\/j.ejmech.2020.112217","volume":"193","author":"X Fan","year":"2020","unstructured":"Fan X, Li J, Deng X, Lu Y, Feng Y, Ma S, et al. Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. Eur J Med Chem. 2020;193:112217. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112217.","journal-title":"Eur J Med Chem"},{"key":"907_CR24","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1021\/acschemneuro.3c00149","volume":"14","author":"J-H Su","year":"2023","unstructured":"Su J-H, Wu G-P, Peng X, Zhao G-Q, Peng Y, Zhang H-H, et al. Neuroprotective Effects of an N -Salicyloyl Tryptamine Derivative against Cerebral Ischemia\/Reperfusion Injury. ACS Chem Neurosci. 2023;14:2146\u201358. https:\/\/doi.org\/10.1021\/acschemneuro.3c00149.","journal-title":"ACS Chem Neurosci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00907-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:09:01Z","timestamp":1790705341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00907-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":24,"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00907-w","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"<b>Ethics and consent to participate<\/b>.","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}